Containing -c(=x)x- Wherein The X's Are The Same Or Diverse Chalcogens Patents (Class 536/18.2)
-
Patent number: 10072100Abstract: Compositions comprising oxidized poly alpha-1,3-glucan compounds are disclosed herein. Oxidized poly alpha-1,3-glucan compounds are produced by contacting poly alpha-1,3-glucan under aqueous conditions with at least one N-oxoammonium salt.Type: GrantFiled: June 1, 2017Date of Patent: September 11, 2018Assignee: E I DU PONT DE NEMOURS AND COMPANYInventors: Rakesh Nambiar, Jayme L Paullin, Andrea M Perticone, T Joseph Dennes
-
Patent number: 9227908Abstract: In a process for producing a tetrabromophthalic diester composition, a liquid reaction mixture is prepared comprising tetrabromophthalic anhydride (TBPA), a C2 to C6 polyhydric aliphatic alcohol (PAA) and an alkylene oxide (AO) selected from the group consisting of ethylene oxide and propylene oxide, said reaction mixture being substantially free of an organic solvent. While agitating the reaction mixture, the temperature of the reaction mixture is raised to at least 50° C. to allow the TBPA to react with the PAA and AO to produce a diester composition. The reaction is terminated when the diester composition has an acid value equal to or less than 0.25 mg KOH/gm of the diester composition.Type: GrantFiled: December 29, 2010Date of Patent: January 5, 2016Assignee: Chemtura CorporationInventors: David W. Bartley, Roy Pickering, Thomas G. Ray
-
Patent number: 9169191Abstract: The invention provides a method of preparing ?-erythritol fatty acid monoester, including: subjecting a fatty acid and erythritol to esterification reaction in the presence of an acid catalyst, a water carrier and an optional phase transfer catalyst, wherein the molar ratio of the fatty acid to erythritol is 1:2 to 1:3, and the temperature of the esterification reaction is 80-100° C. In addition, the invention further provides a method of preparing 2,3-erythritol fatty acid diester, including: subjecting a fatty acid and erythritol to esterification reaction in the presence of an acid catalyst and a water carrier, wherein the molar ratio of the fatty acid to erythritol is 2:1 to 3:1, and the temperature of the esterification reaction is 120-160° C.Type: GrantFiled: May 24, 2013Date of Patent: October 27, 2015Assignee: Wilmar (Shanghai) Biotechnology Research & Development Center Co., LTDInventors: Zonghui Ma, Yan Zheng, Tiankui Yang, Xuebing Xu
-
Publication number: 20150126465Abstract: The present invention relates to the process for producing compounds derived from the plant Pyrostegia venusta (P. venusta), pharmaceutical compositions comprising the same and its medical uses, especially as antimicrobial.Type: ApplicationFiled: May 14, 2012Publication date: May 7, 2015Applicants: ASSOCIÇÃO DE ENSINO DE RIBEIRÃO PRETO, BIOTEC - BIO TECNOLOGIA LTDAInventors: Jardel Massari, Ana Maria Soares Pereira, Sarazete Izidia Vez Pereira, Camilla Hernandes, Bianca Waleria Bertoni, Silvia Helena Taleb Contini
-
Publication number: 20150119346Abstract: Glycosylated valproic acid and its analogs are provided. In some embodiments, the glycosylated valproic acid and its analogs have improved solubility and are ideal for drug delivery to treat a variety of diseases.Type: ApplicationFiled: December 29, 2014Publication date: April 30, 2015Inventors: Norman S. HEYMAN, Brian K. SHULL
-
Patent number: 9018363Abstract: The invention disclosed in this document is related to the field of pesticides and their use in controlling pests. A compound having the following structure is disclosed.Type: GrantFiled: March 15, 2012Date of Patent: April 28, 2015Assignee: Dow AgroSciences LLCInventors: Gary D. Crouse, Thomas C. Sparks, CaSandra L. McLeod, David A. Demeter, Kristy Bryan, Annette V. Brown, William H. Dent, III, Denise P. Cudworth, Jaime S. Nugent, Ricky Hunter, Jack G. Samaritoni
-
Publication number: 20150111842Abstract: Provided are an attractant for bone marrow stem cells containing at least one of cinnamtannin B1 and pentagalloylglucose, and a method for attracting bone marrow stem cells in which bone marrow stem cells are attracted by the attractant.Type: ApplicationFiled: May 31, 2013Publication date: April 23, 2015Applicants: PIAS CORPORATION, OSAKA UNIVERSITYInventors: Tadashi Furumoto, Koichi Nakaoji, Kazuhiko Hamada, Noriyasu Ozawa, Yuta Inami, Misaki Toyoshima, Kosuke Fujita, Akito Maeda, Yasufumi Kaneda, Katsuto Tamai
-
Publication number: 20150112049Abstract: The present invention provides a high-purity acid-form sophorolipid (SL)-containing composition characterized by substantially not containing acetic acid. The high-purity acid-form SL-containing composition can be produced, for example, by the following method: (i) adjusting the pH of a partially purified acid-form SL-containing composition to an acidic range; and (ii-a) subjecting an acidified partially purified acid-form SL-containing composition obtained in step (i) to chromatography to acquire a fraction containing an acid-form SL, or (ii-b) leaving the acidified partially purified acid-form SL-containing composition obtained in step (i) to stand under a low-temperature condition to acquire a resulting gelled object.Type: ApplicationFiled: March 1, 2013Publication date: April 23, 2015Applicant: Saraya Co., Ltd.Inventors: Yoshihiko Hirata, Mizuyuki Ryu, Hitoshi Ito, Michiaki Araki
-
Publication number: 20150087817Abstract: A composition comprising: (a) from 20 to 60 wt % of a saccharide component comprising from two to five sugar ring units having polymerized units of at least one alkylene oxide selected from the group consisting of ethylene oxide, propylene oxide and butylene oxide bonded to oxygen atoms on said sugar rings and at least three acetoacetyl groups bonded to terminal oxygen atoms of said polymerized units of at least one alkylene oxide; and (b) from 40 to 80 wt % of a non-saccharide component comprising a polyol unit not containing a sugar ring and having a hydroxyl functionality from two to five; said polyol unit having polymerized units of at least one alkylene oxide selected from the group consisting of ethylene oxide, propylene oxide and butylene oxide bonded to hydroxyl oxygen atoms of the polyol and at least two acetoacetyl groups bonded to terminal oxygen atoms of said polymerized units of at least one alkylene oxide; wherein total polymerized units of at least one alkylene oxide comprise from 20 to 80 wt %Type: ApplicationFiled: September 15, 2014Publication date: March 26, 2015Inventors: Sudhakar Balijepalli, Paul Doll, Alvin M. Maurice, Jenny B. Werness
-
Publication number: 20150051387Abstract: Disclosed are water-soluble platinum complexes for tumor treatment and preparation method, said platinum complexes being shown as formula (I); The present platinum complexes exhibiting superior cytotoxicity and efficacy compare to the clinical drug oxaliplatin, the design strategy of the present platinum complexes is to enhance the solubility and stability favor its clinical use.Type: ApplicationFiled: June 22, 2012Publication date: February 19, 2015Applicant: GUDUI BIOPHARMA TECHNOLOGY INC.Inventors: Yiqiang Wang, Yang Liu
-
Publication number: 20150011741Abstract: The present invention provides methods for the isolation of an amphipathic, hydrophobic or hydrophilic compound from a medium that is either hydrophilic or hydrophobic, respectively, said methods comprising allowing the formation and/or accumulation of foam comprising said compound at the medium-gas interface, applying said foam directly onto an adsorbent which effects collapse of said foam, and isolating said adsorbed compound by desorption.Type: ApplicationFiled: December 12, 2012Publication date: January 8, 2015Applicant: TECHNISCHE UNIVERSITAET DORTMUNDInventors: Lars Blank, Benjamin Kuepper, Eva Maria Del Amor Villa, Rolf Wichmann, Christian Nowacki
-
Publication number: 20150011740Abstract: Disclosed are fluorine-containing highly water-soluble platinum complexes for tumor treatment and preparation method, said platinum complexes being shown as formula (I); The present fluorine-containing platinum complexes exhibiting superior cytotoxicity and efficacy compare to the clinical drug oxaliplatin, the design strategy of the present platinum complexes is to enhance the solubility and stability favor its clinical use.Type: ApplicationFiled: June 22, 2012Publication date: January 8, 2015Applicants: GUDUI BIOPHARMA TECHNOLOGY INC., JUANG SU VANGUARD PHARMACY CO.LTD,Inventors: Yiqiang Wang, Yang Liu
-
Publication number: 20150011138Abstract: The present invention provides a composition, a gypsum board and their preparation method and the use of ascorbic acid as an anti-sagging additive in a gypsum board. Said gypsum board comprises set gypsum prepared from the composition; while said composition comprises hemi-hydrate gypsum, water and a compound comprising group and no carboxylate groups. The set gypsum prepared from the said composition shows better anti-sagging or deformation resisting property. The gypsum board of the present invention is hardly distorted and has stronger stability even in the condition of high humidity, thus improve the quality of the gypsum board to meet the demands of the customer.Type: ApplicationFiled: December 3, 2012Publication date: January 8, 2015Applicant: SAINT-GOBAIN PLACOInventors: Xiaotong Gao, Huifen Li, Hao Song, Ke Zhang
-
Patent number: 8921533Abstract: Glycosylated valproic acid and its analogs are provided. In some embodiments, the glycosylated valproic acid and its analogs have improved solubility and are ideal for drug delivery to treat a variety of diseases.Type: GrantFiled: July 25, 2012Date of Patent: December 30, 2014Assignee: Chromatin TechnologiesInventors: Norman S. Heyman, Brian K. Shull
-
Patent number: 8906868Abstract: The present invention relates to antimicrobial agents. Some embodiments include compounds, compositions, methods of preparation, and methods of treatment using new aminoglycosides and aminoglycoside derivatives.Type: GrantFiled: May 12, 2011Date of Patent: December 9, 2014Assignee: Rempex Pharmaceuticals, Inc.Inventors: Tomasz W. Glinka, Olga Rodny
-
Publication number: 20140357582Abstract: Foods and beverages, quasi-drugs, and pharmaceuticals that exhibit high antioxidative activity in the living body for a long time are provided. High antioxidative activity can be imparted by incorporating desrhamnosyl acteoside in an olive extract. A desrhamnosyl acteoside-containing composition can be prepared by treating an acteoside-containing composition with glycosidase.Type: ApplicationFiled: January 17, 2013Publication date: December 4, 2014Applicant: Suntory Holdings LimitedInventors: Yuko Fukui, Yoshiko Ono, Mitsuru Maeda, Namino Tomimori
-
Patent number: 8889651Abstract: The invention relates to trehalose derivatives with general formula (I), a preparation method and uses thereof, wherein 6,6?-bis(2,3-dimethoxybenzoyl)-?,?-D-trehalose has anti-colon cancer 26-L5 cell invasion activity which is better than that of a natural product Brartemicin, IC50 is 0.10 ?g/mL (0.15 ?M), and when the IC50 is 10 ?g/mL, 6,6?-bis(2,3-dimethoxybenzoyl)-?,?-D-trehalose has no cytotoxicity, shows high-selectivity anti-tumor invasion activity and can be used for preparing medicaments for preventing and treating invasion and metastasis of colon cancer and the like.Type: GrantFiled: December 30, 2010Date of Patent: November 18, 2014Assignee: Joyochem Co., Ltd.Inventors: Zhaopeng Liu, Yongli Jiang
-
Publication number: 20140336369Abstract: Processes are disclosed for the synthesis of the Factor Xa anticoagulant fondaparinux and related compounds. Protected pentasaccharide intermediates and efficient and scalable processes for the industrial scale production of fondaparinux sodium by conversion of the protected pentasaccharide intermediates via a sequence of deprotection and sulfonation reactions are provided.Type: ApplicationFiled: July 23, 2014Publication date: November 13, 2014Applicant: APICORE US LLCInventors: Ravishanker Kovi, Ashish Naik, Brijesh Patel, Muralikrishna Madala
-
Publication number: 20140322755Abstract: The present disclosure provides a sophorolipid composition that can be used for inducing protein expression in a fermentation host. The sophorolipid composition described herein can be prepared from a natural sophorolipid mixture. Acid treatment of the natural sophorolipid mixture results in a mixture of monoacetylated, deacetylated, and/or diacetylated sophorolipids. The chemically modified sophorolipid composition, or isolated components of the chemically modified sophorolipid composition, can be used as inducers for protein production in filamentous fungi.Type: ApplicationFiled: June 25, 2012Publication date: October 30, 2014Inventor: Tom Tao Huang
-
Publication number: 20140315834Abstract: The present invention provides novel compounds and pharmaceutical compositions for the prevention and/or treatment of cancer and precancerous conditions thereof, for the treatment of pain and fever, for the treatment of skin disorders, and for treating and/or preventing inflammation-related diseases and/or cardiovascular diseases. The compounds of the invention also have analgesic properties and anti-platelet properties. The compounds of the invention may be provided to animals, including mammals and humans, by administering a suitable pharmaceutical dose in a suitable pharmaceutical dosage form. The compounds of the invention have improved efficacy and safety, including higher potency and/or fewer or less severe side effects, than conventional therapies. The compounds of the invention comprise a biologically active moiety or portion (A) that has, or is modified to have at least one carboxyl group.Type: ApplicationFiled: September 23, 2013Publication date: October 23, 2014Applicant: Medicon Pharmaceuticals, Inc.Inventor: Basil RIGAS
-
Publication number: 20140303360Abstract: The present invention relates to compounds involved in nematode signaling.Type: ApplicationFiled: August 8, 2012Publication date: October 9, 2014Applicants: California Institute of Technology, Boyce Thompson Institute for Plant ResearchInventors: Frank C. Schroeder, Stephan H. Von Reuss, Andrea Choe, Paul W. Stemberg
-
Publication number: 20140294925Abstract: Provided herein are methods of treating a superbug infection in a subject that include administering to the subject a therapeutically effective dose of ramoplanin in combination with a therapeutically effective dose of one or more rhamnolipids, thereby treating the superbug infection. The superbug may be vancomycin-resistant Enterococcus, Clostridium difficile, or multidrug-resistant Clostridium difficile. The one or more rhamnolipids may include monorhamnolipid Rha-C10-C10, dirhamnolipid Rha-Rha-C10-C10, or monorhamnolipid Rha-C10-C10 and dirhamnolipid Rha-Rha-C10-C10. Also disclosed are pharmaceutical compositions that include ramoplanin, one or more rhamnolipids, and a pharmaceutically acceptable carrier, as well as formulations for preventing superbug infection.Type: ApplicationFiled: March 7, 2014Publication date: October 2, 2014Applicant: AGAE Technologies LLCInventor: Xihou Yin
-
Patent number: 8835614Abstract: Provided herein are conjugates comprising a protein and an oligosaccharide of one of Formulae I-VI. Also provided herein are pharmaceutical compositions comprising such conjugates. Further provided herein are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-glycoprotein conjugate.Type: GrantFiled: December 11, 2009Date of Patent: September 16, 2014Assignee: Genzyme CorporationInventors: Luis Z. Avila, Clark Q. Pan, Patrick Finn, John Harrahy, Qun Zhou, Yunxiang Zhu, Paul A. Konowicz, Duncan E. Paterson, Andreas Peer, Joseph P. Kutzko, Michael R. Reardon, James E. Stefano, Xiaoyang Zheng, Robert J. Miller, Lauren Young
-
Patent number: 8829168Abstract: The invention relates to methods for making deoxyribofuranose compounds such as compound (2) which are useful intermediates in the preparation of pharmaceutical compounds such as 5-amino-3-(2?-O-acetyl-3?-deoxy-?-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one and the like.Type: GrantFiled: November 16, 2009Date of Patent: September 9, 2014Assignee: Anadys Pharmaceuticals, Inc.Inventor: Gregory J. Haley
-
Publication number: 20140235814Abstract: The present invention relates to the use of a compound of formula (I): wherein: R represents a linear or branched alkyl group, comprising from 3 to 27 carbon atoms, said alkyl group being substituted with at least two hydroxyl groups, and which may optionally contain one or more unsaturations; and R? is selected from sugars or sugar-alcohols; for preparing polyurethanes and polyesters.Type: ApplicationFiled: October 2, 2012Publication date: August 21, 2014Inventors: Henri Cramail, Aurélie Boyer, Cédric Epoune Lingome, Carine Alfos, Benoit Gadenne, Eric Cloutet, Yves Queneau, Sylvie Moebs
-
Publication number: 20140227239Abstract: It is an object of the present invention to provide a growth hormone secretagogue that is excellent in effect of promoting secretion of a growth hormone and is orally available. The growth hormone secretagogue of the present invention contains one or more selected from the group consisting of S-adenosylmethionine and/or a salt thereof, a Siberian larch extract, an olive extract, and a stilbene-based compound as an active ingredient. S-adenosylmethionine and/or the salt thereof may be a form itself of chemically synthesized S-adenosylmethionine and/or the salt thereof, or may be a microbial cell or a culture containing S-adenosylmethionine and/or the salt thereof. The stilbene-based compound may be an extract extracted from a Vitaceae plant or a Gnetaceae plant. The olive extract may be an extract separated from a fruit of olive.Type: ApplicationFiled: March 2, 2012Publication date: August 14, 2014Applicant: LION CORPORATIONInventors: Toshio Gokita, Ikuko Kamada, Kiwamu Suzuki, Hiroaki Kambayashi
-
Patent number: 8802834Abstract: Disclosed herein are compositions that include a blend of sucrose polyesters, wherein each sucrose polyester includes a sucrose moiety and a plurality of fatty acid ester moieties, wherein from about 50% to about 90%, by weight, of the combined fatty acid ester moieties of the sucrose polyesters in the blend are palmitic fatty acid ester moieties.Type: GrantFiled: May 24, 2012Date of Patent: August 12, 2014Assignee: The Procter & Gamble CompnayInventors: Peter Yau-Tak Lin, Deborah Jean Back, Donald Benjamin Appleby, James M. Robertson, Steven Robert Baker
-
Publication number: 20140221633Abstract: The present invention provides a one-pot method of preparing an unprotected ?-O-glycolipid. The first step involves contacting a protected ?-iodo sugar with a catalyst and a lipid comprising a hydroxy group, under conditions sufficient to prepare a protected ?-O-glycolipid. The second step involves deprotecting the protected ?-O-glycolipid under conditions sufficient to prepare the unprotected ?-O-glycolipid, wherein the contacting and deprotecting steps are performed in a single vessel. The present invention also provides a one-pot method of preparing an unprotected ?-O-glycolipid following the steps for the preparation of the unprotected ?-O-glycolipid.Type: ApplicationFiled: January 6, 2014Publication date: August 7, 2014Inventors: Jacquelyn Gervay-Hague, Wenjun Du, Suvarn S. Kulkarni, Matthew Schombs
-
Publication number: 20140194606Abstract: Extracted olive oil having extremely less olive smell and excellent skin permeability, and having an extremely higher antioxidative property than that of common olive oil. Also provided is a method for producing extracted olive oil including: crushing olive fruits and olive leaves; and producing the extracted olive oil from an obtained paste-like matter, where the olive fruits and the olive leaves are lactic fermented before or after the crushing step or during the crushing step.Type: ApplicationFiled: March 10, 2014Publication date: July 10, 2014Applicant: SHODOSHIMA HEALTHY LAND CO., LTD.Inventor: Yoshihiko YAGYU
-
Publication number: 20140194536Abstract: The present invention relates to a liquid crystal compound that can be used as a base for injection formulations. The present invention provides an amphipathic compound having the following general formula (I): wherein X and Y each denotes a hydrogen atom or together denote an oxygen atom, n denotes an integer from 0 to 2, m denotes the integer 1 or 2, and R denotes a hydrophilic group generated by removal of one hydroxyl group from any one selected from the group consisting of glycerol, erythritol, pentaerythritol, diglycerol, triglycerol, xylose, sorbitol, ascorbic acid, glucose, galactose, mannose, dipentaerythritol, maltose, mannitol, and xylitol; as well as a base for injection formulations and depot formulation comprising the same.Type: ApplicationFiled: February 28, 2014Publication date: July 10, 2014Applicant: Chemgenesis IncorporatedInventors: Yutaka Ikeda, Jun Yamashita, Ichiro Hijikuro, Satoshi Imuta, Yasuhiro Hiroki, Takashi Takahashi
-
Publication number: 20140178444Abstract: The invention relates to the use of, and methods of use employing, certain glycolipid compounds as defined in detail below and having preservative or antimicrobial properties, novel compounds of the glycolipid class, and related invention embodiments. The compounds have the formula I wherein m is 3 to 5, n is 2 to 5, o is 0 or 1 and p is 3 to 17, with the proviso that the sum m+n+o+p is not less than 14; and R is a carbohydrate moiety bound via one of its carbon atoms to the binding oxygen, and/or a physiologically, especially pharmaceutically or nutraceutically or cosmetically, acceptable salt thereof, or an ester thereof, as such or in the form of a composition, where the compound may be present in open chain form and/or in the form of a lactone (FIG. 1).Type: ApplicationFiled: June 6, 2012Publication date: June 26, 2014Applicant: IMD NATURAL SOLUTIONS GMBHInventors: Marc Stadler, Jens Bitzer, Bärbel Köpcke, Kathrin Reinhardt, Jana Moldenhauer
-
Publication number: 20140179622Abstract: The present invention relates to a novel compound isolated from Quamoclit sp., and more particularly to a novel compound isolated from Quamoclit sp. and a composition for preventing or treating diabetes and its complications comprising the compound as an active ingredient. The novel compound isolated from Quamoclit sp. according to the present invention has excellent effects on lowering blood sugar, promoting insulin secretion, inhibiting VEGF expression, and so on. Thus, the present invention not only functions to prevent or treat diabetes and its complications, but also functions to promote treatment effects when treated together with conventional diabetes medicines.Type: ApplicationFiled: June 28, 2012Publication date: June 26, 2014Applicant: Korea Research Institute of Bioscience and BiotechnologyInventors: Bong Hyun Chung, So Yeon Yi, Ui Jin Lee
-
Publication number: 20140155339Abstract: Compositions comprising hydroxytyrosol-containing formulations and treatment regiments comprising hydroxytyrosol and/or oleuropein and chemotherapeutic agents are disclosed. Compositions and/or regiments may optionally include the administration of vitamins, minerals, and anti-oxidants. Methods for using these compositions and treatment regimens for treating subjects for diseases, such as a malignancy, and for inducing or enhancing angiogenesis, treating or preventing oxidative stress, for treating or preventing high glucose-induced dysfunction, treating or preventing chemotherapy-induced dysfunction, and for improving cell viability are provided. Various methods for use of the hydroxytyrosol compositions for inhibition of lysine specific demethylase 1 (LSD1) in various cancers are also provided.Type: ApplicationFiled: November 27, 2013Publication date: June 5, 2014Inventors: Darlene E. McCord, Thomas Karagiannis
-
Publication number: 20140148588Abstract: A process for isolating rhamnolipids is provided. The process includes providing an aqueous medium containing at least one rhamnolipid and having a pH of less than 6. Next, the aqueous medium is brought into contact with at least one organic solvent to provide a multiphase system and then the aqueous phase is separated off. The pH is then increased to a value of 6 or more to provide a multiphase organic system. Next, a rhamnolipid-enriched organic phase is separated off. An optional step of further purifying the rhamnolipid may be performed.Type: ApplicationFiled: November 25, 2013Publication date: May 29, 2014Applicant: Evonik Industries AGInventors: Martin Schilling, Marius Ruetering, Verena Dahl, Fabien Cabirol
-
Publication number: 20140141082Abstract: The invention relates to unique compositions containing enriched and purified natural crocin and/or crocetin for prevention and/or treatment of cancers and other conditions and diseases. Compositions comprise mainly enriched or purified natural crocin or crocetin or combination of both and possible other active phytochemicals. A composition is used as functional food, drink, dietary supplement, or therapeutic dosage to a human orally or through other appropriate way (parenteral, percutaneous, rectal, mucosal, intranasal or topical administration). A method of natural crocin and crocetin enriching and purification is revealed.Type: ApplicationFiled: November 6, 2013Publication date: May 22, 2014Inventor: Song Gao
-
Publication number: 20140142287Abstract: The present invention provides carbohydrate-based surfactants and methods for producing the same. Methods for producing carbohydrate-based surfactants include using a glycosylation promoter to link a carbohydrate or its derivative to a hydrophobic compound.Type: ApplicationFiled: September 30, 2013Publication date: May 22, 2014Applicant: THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONAInventors: Jeanne E. Pemberton, Robin L. Polt, Raina M. Maier, Clifford S. Coss
-
Publication number: 20140121175Abstract: The invention is intended to provide an excellent antitumor agent. An antitumor agent contains a glycolipid glycoside compound represented by Formula (1) or a pharmacologically acceptable salt thereof as an active ingredient: in the formula, R1 to R4 are the same as or different from each other and represent an alkanoyl group or a hydrogen atom, and A represents a sugar alcohol residue or a polyol residue.Type: ApplicationFiled: May 28, 2012Publication date: May 1, 2014Applicant: KINKI UNIVERSITYInventors: Reiko Sugiura, Osamu Muraoka, Nozomi Tsutsui, Ayako Kita, Tatsuki Kunoh
-
Patent number: 8685942Abstract: A composition of matter comprising sophorolipids as antimicrobial agents, antifungal agents, biopesticides, for uses as drugs to treat HIV, septic shock, cancer, asthma, dermatological conditions, as spermicidal agents, as anti-inflammatory drugs, as ingredients in cosmetics and building blocks for monomers and polymers and self-assembled templates for further chemical elaboration.Type: GrantFiled: April 5, 2011Date of Patent: April 1, 2014Inventors: Richard A. Gross, Mark H. Schofield
-
Publication number: 20140065250Abstract: Identification and use of compounds which inhibit the expression or activity of micro-RNAs for preventing and/or attenuating ageing. An in vitro method for screening for candidate compounds for preventing and/or attenuating ageing of the skin including (a) bringing at least one test compound in contact with a sample of fibroblasts, (b) measuring the expression or the activity of at least one microRNA chosen from miR-134 and miR-152 in said fibroblasts, and (c) selecting the compounds for which an inhibition of at least 20%, preferably at least 30%, preferably at least 40% of the expression or an inhibition of at least 20%, preferably at least 30%, preferably at least 40% of the activity of at least one microRNA is measured in the fibroblasts treated in (a) compared with the untreated fibroblasts.Type: ApplicationFiled: August 28, 2013Publication date: March 6, 2014Applicant: CHANEL PARFUMS BEAUTEInventors: Eleonora CANDI, Gerry MELINO, Gaelle SAINTIGNY, Christian MAHE
-
Patent number: 8664373Abstract: The present invention provides a low-cost, efficient method for producing a glycolipid biosurfactant, in particular, lactonic sophorose lipids. This method is characterized by culturing a microorganism capable of producing the biosurfactant under limited oxygen supply. The present invention enables preferential production of lactonic sophorose lipids and facilitates recovery of the lactonic sophorose lipids in a solid form. Further, the present invention enables production of high purity acidic sophorose lipids by hydrolyzing high purity lactonic sophorose lipids produced by the above method. The present invention also provides lactonic sophorose lipids that possess strong antibacterial and antifungal activities, and an antibacterial and/or antifungal agent containing the sophorose lipids.Type: GrantFiled: October 23, 2009Date of Patent: March 4, 2014Assignee: Kaneka CorporationInventors: Satohiro Yanagisawa, Shigeru Kawano, Yoshihiko Yasohara
-
Publication number: 20140031536Abstract: The invention provides methods and compositions for preparing antibodies and antibody derivatives with reduced core fucosylation.Type: ApplicationFiled: October 1, 2013Publication date: January 30, 2014Applicant: Seattle Genetics, Inc.Inventors: Stephen C. Alley, Scott C. Jeffrey, Django Sussman, Dennis R. Benjamin, Brian Toki, Patrick J. Burke
-
Publication number: 20140024816Abstract: A composition of matter comprising sophorolipids as antimicrobial agents, antifungal agents, biopesticides, for uses as drugs to treat HIV, septic shock, cancer, asthma, dermatological conditions, as spermicidal agents, as anti-inflammatory drugs, as ingredients in cosmetics and building blocks for monomers and polymers and self-assembled templates for further chemical elaboration.Type: ApplicationFiled: September 19, 2013Publication date: January 23, 2014Inventors: Richard A. Gross, Mark H. Schofield
-
Publication number: 20130345114Abstract: The use of an agent in the manufacture of a medicament to affect an allergic condition and/or a hypersensitivity condition is described. The agent is capable of modulating a ganglioside associated activity. The agent is not coupled to an antigen. The modulation of the ganglioside associated activity affects an allergic condition and/or a hypersensitivity condition.Type: ApplicationFiled: January 18, 2013Publication date: December 26, 2013Applicant: TRIDENT PHARMACEUTICALS, INC.Inventor: TRIDENT PHARMACEUTICALS, INC.
-
Publication number: 20130345412Abstract: The invention relates to a radical-initiated thiol-ene or thiol-yne “click” reaction that provides a simple and efficient route to diverse trialkoxysilanes. Trialkoxysilanes made in this way are obtained in quantitative to near-quantitative yields with high purity without any or minimal purification. A wide range of functional groups is tolerated in this approach, and even complex alkenes click with the silane precursors. The modular nature of these radical-based thiol-ene or thiol-yne “click” reactions allows a wide variety of pendant groups to be coupled to silane compounds that can then be coupled to a wide variety surfaces in order to modify their material properties. Consequently, such radical initiated thiol-ene and thiol-yne reactions provide facile and efficient methods for preparing an enormous number of surface-active functional trialkoxysilanes.Type: ApplicationFiled: March 22, 2012Publication date: December 26, 2013Applicant: The Regents of the University of CaliforniaInventors: Robin L. Garrell, Alexander K. Tucker-Schwartz
-
Publication number: 20130338349Abstract: The present invention provides (i) processes for preparing a 2?-deoxy-2?-fluoro-2?-methyl-D-ribonolactone derivatives, (ii) conversion of intermediate lactones to nucleosides with potent anti-HCV activity, and their analogues, and (iii) methods to prepare the anti-HCV nucleosides containing the 2?-deoxy-2?-fluoro-2?-C-methyl-?-D-ribofuranosyl nucleosides from a preformed, preferably naturally-occurring, nucleoside.Type: ApplicationFiled: June 13, 2013Publication date: December 19, 2013Inventors: Byoung-Kwon Chun, Peiyuan Wang, Jinfa Du, Suguna Rachakonda
-
Publication number: 20130331346Abstract: The invention relates to trehalose derivatives with general formula (I), a preparation method and uses thereof, wherein 6,6?-bis(2,3-dimethoxybenzoyl)-?,?-D-trehalose has anti-colon cancer 26-L5 cell invasion activity which is better than that of a natural product Brartemicin, IC50 is 0.10 ?g/mL (0.15 ?M), and when the IC50 is 10 ?g/mL, 6,6?-bis(2,3-dimethoxybenzoyl)-?,?-D-trehalose has no cytotoxicity, shows high-selectivity anti-tumor invasion activity and can be used for preparing medicaments for preventing and treating invasion and metastasis of colon cancer and the like.Type: ApplicationFiled: December 30, 2010Publication date: December 12, 2013Applicant: JOYOCHEM CO., LTDInventors: Zhaopeng Liu, Yongli Jiang
-
Publication number: 20130331466Abstract: A method for the development of a library of modified sophorolipids using a wide-range of chemical and enzyme catalyst tools to identify modified sophorolipids that can be used in pure form, as mixtures with other modified sophorolipids, as mixtures with natural sophorolipids, as mixtures with modified and natural sophorolipids, and as mixtures with other compounds known by one skilled in the art for use in the dispersion, solubilization or emulsification of various oil types and nutraceuticals, and modified sophorolipids for use in dispersion, solubilization or emulsification processes.Type: ApplicationFiled: May 27, 2013Publication date: December 12, 2013Inventors: Richard A. Gross, Thavasi Rengathavasi, Amanda Koh, Yifeng Peng
-
Publication number: 20130310332Abstract: The present document describes a neutraceutical, cosmeceuticals, functional food, pharmaceutical, food ingredient, and non-food ingredient compositions comprising sugar maple extract, essential oil compositions comprising oil extracted from an Acer tree, sweetening compositions containing sugar extracted from maple tree leaves, food ingredients comprising maple tree extract, cosmetic composition comprising maple tree extracts, infusion compositions prepared from maple tree leaves, maple roots, maple wood, maple stems of leaves and samara, and stems/twigs as well as compounds isolated from sugar maple biomass and the methods of extracting the same.Type: ApplicationFiled: October 14, 2011Publication date: November 21, 2013Applicants: UNIVERSITY OF RHODE ISLAND, FEDERATION DES PRODUCTEURS ACERICOLES DU QUEBECInventors: Julie Barbeau, Genevieve Beland, Navindra P. Seeram, Tao Yuan
-
Publication number: 20130310331Abstract: There is provided an antidiabetic enolic glucoside of phenylpyruvic acid and derivatives thereof for use as medicaments, especially normoglycemic agents, i.e. for lowering blood glucose levels to normal levels in mammals that are obese, pre-diabetic or have diabetes, obesity and/or syndrome X. Hence the compounds of the present invention help to manage blood sugar levels, i.e. helping the body by balancing the blood sugar levels; helping to keep balanced blood glucose levels, particularly in humans with diabetes; aiding by enhancing the glucose uptake by the cells and by reducing sugar levels, thus improving or restoring the glucose tolerance; optimizing the glycemic response; normalizing the glucose tolerance.Type: ApplicationFiled: October 7, 2010Publication date: November 21, 2013Applicant: ZADEC APSInventors: Elizabeth Joubert, Stephen John Fey, Johan Louw, Trond Ulven, Rahul Tyagi
-
Patent number: 8580751Abstract: The invention provides esterified ?-galactosylceramides effective for cancer treatment and the like, and a medicament containing same. In particular, the invention relates to a compound represented by the formula (I): wherein R1 is a hydrocarbon group having a carbon number of 1 to 30, R2 is a hydrocarbon group having a carbon number of 1 to 20, R3 is a hydrogen atom or hydrocarbon group having a carbon number of 1 to 5, R4 and R5 are the same or different and each is a hydrogen atom or a hydrocarbon group having a carbon number of 1 to 5, or R4 and R5 in combination form a divalent hydrocarbon group having a carbon number of 1 to 5, and optionally form a ring structure together with the adjacent ethylenedioxy, or a salt thereof.Type: GrantFiled: September 11, 2009Date of Patent: November 12, 2013Assignee: RikenInventors: Masao Shiozaki, Takuya Tashiro, Kenji Mori, Ryusuke Nakagawa, Hiroshi Watarai, Masaru Taniguchi